TrialBMC cancer2020

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).

Kyoichi Kaira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.